Immunogenomic analyses of high-grade serous ovarian cancer (HGSOC)

<p>High-grade serous ovarian cancer (HGSOC) remains the most lethal gynecologic malignancy despite new therapeutic concepts, including poly-ADP-ribose polymerase inhibitors (PARPis) and&nbsp;antiangiogenic therapy. In this study, we have analyzed homologous recombination repair deficiency (HRD) or BRCAness and the composition of the tumor microenvironment, which appear to play a critical role in determining&nbsp;the therapeutic response of combination immunotherapy with&nbsp;PARPis. The used datasets include RNA sequencing data and clinical information from patients of a new HGSOC cohort of the Medical University of Innsbruck (MUI) (n=60) and analyzed data from The Cancer Genome Atlas (TCGA) (n=226).</p>